Ona Therapeutics to develop ADC with WuXi’s payload-linker platform

WuXi XDC Cayman is to provide Ona Therapeutics with an exclusive global licence to its WuXiTecan-2 platform to develop an ADC candidate. The deal grants Ona Therapeutics rights to develop an ADC targeting a single undisclosed target. Ona Therapeutics develops ADCs for treatment-resistant cancers using a discovery platform. Credit: Gorodenkoff / Shutterstock.com. WuXi XDC Cayman has signed an agreement to provide Ona Therapeutics with an exclusive global licence to its WuXiTecan-2 payload-linker technology platform for the development of an antibody-drug conjugate (ADC) candidate. The deal grants Ona Therapeutics rights to develop the ADC targeting a single undisclosed target. LOA and…

Source: Pharmaceutical Technology